Several outlets are reporting on the most anticipated drug launches of 2026, with some highlighting the potential for blockbuster contenders and others noting trends to watch in the biopharma industry. The list of anticipated launches appears to include cardiometabolic drugs, although the specific details and rankings may vary. It is unclear which drugs will ultimately be launched or their potential impact, as some reports also mention clinical trials to watch in the second half of the year.